VIA
PGNX

Vantage Investment Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Vantage Investment Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2K Hold
250
– – ﹤0.01% 719
2018
Q2 		$2K Buy
+250
New +$1.91K ﹤0.01% 712

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Vantage Investment Advisors's PGNX Position: Q3 2018 in Review

Vantage Investment Advisors held its Progenics Pharmaceuticals Inc (PGNX) position steady in Q3 2018 at 250 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #719.

Vantage Investment Advisors first reported a position in PGNX in Q2 2018 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Vantage Investment Advisors held 250 shares of Progenics Pharmaceuticals Inc worth $2K as of Q3 2018.
  • Vantage Investment Advisors left its Progenics Pharmaceuticals Inc share count unchanged in Q3 2018.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #719 holding.
  • Vantage Investment Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.